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Nai-Jung Chiang1,2, Li-Tzong Chen1,2,3,4*, Chia-Rung Tsai1 and Jeffrey S Chang1*Abstract
Background: To investigate the incidence of gastrointestinal stromal tumors (GISTs) in Taiwan and the impact of
imatinib on the overall survival (OS) of GIST patients.
Methods: GISTs were identified from the Taiwan Cancer Registry (TCR) from 1998 to 2008. The age-adjusted
incidence rates and the observed OS rates were calculated. Cox proportional hazards models were applied to
examine the mortality risk in three time periods (1998–2001, 2002–2004, 2005–2008) according to the application
and availability of imatinib.
Results: From 1998 to 2008, 2,986 GISTs were diagnosed in Taiwan. The incidence increased from 1.13 per 100,000
in 1998 to 1.97 per 100,000 in 2008. The most common sites were stomach (47-59%), small intestine (31-38%), and
colon/rectum (6-9%). The 5-year observed OS was 66.5% (60.3% for men, 74.2% for women, P < .0001). GISTs in the
stomach had a better 5-year observed OS (69.4%) than those in the small intestine (65.1%) (P < .0001). The outcome
of GIST improved significantly after the more widespread use of imatinib; the 5-year observed OS increased from
58.9% during 1998–2001 to 70.2% during 2005–2008 (P < .0001). Younger age, female sex, stomach location, and
later diagnostic years were independent predictors of a better survival.
Conclusions: The incidence of GIST has been increasing in Taiwan, partially due to the advancement of diagnostic
technology/method and the increased awareness by physicians. The outcome of GIST has improved significantly
with the availability and the wider use of imatinib.
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Gastrointestinal stromal tumors (GISTs) are the most
common mesenchymal neoplasms of the gastrointestinal
system, characterized by an unique histological morph-
ology and the expression of the KIT protein [1]. Previ-
ously, the majority of GISTs were diagnosed as smooth
muscle tumors (e.g. leiomyoma and leiomyosarcoma) or
as tumors of the nerve sheath origin (e.g. schwannoma
and malignant nerve sheath tumors) [2,3]. Because
GISTs were previously difficult to define due to the lack
of specific markers, few epidemiologic studies were* Correspondence: leochen@nhri.org.tw; jeffreychang@nhri.org.tw
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reproduction in any medium, provided the orpublished with no nation-wide cancer registry-based
study of GISTs from Asia [4,5]. The advancement of im-
munohistochemistry, molecular technology and the
identification of KIT oncogene mutation in more than
80% of GISTs have accelerated our understanding of
GISTs [6-8]. In Taiwan, the diagnosis of GISTs by
CD117 or KIT staining was established and widely
adopted since 2002. Prior to 2002, the diagnosis of
GISTs was based on histology and other immunohisto-
chemical markers (CD34, vimentin, keratin, smooth
muscle actin (SMA), and S100) [4,9]. Using the Taiwan
Cancer Registry (TCR) data from 1998 to 2008, our ana-
lysis elucidated the incidence and the distribution of
GISTs before and after the implementation of CD117 or
KIT staining for the definitive diagnosis of GISTs and
compared them to those in the Western countries.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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treatment of primary localized GISTs. The 5-yr survival
rate after complete surgical resection was 50% before the
era of molecular targeted therapy [10,11]. The approval of
imatinib mesylate (Gleevec®, Novartis Pharma, Basel,
Switzerland), an oral inhibitor of KIT and platelet-derived
growth factor receptor, alpha polypeptide (PDGFRA), to
treat metastatic GIST by the USA FDA in 2002 has mark-
edly changed the outcomes and treatment options for
GISTs [12]. In Taiwan, imatinib was approved for reim-
bursement by the National Health Insurance Administra-
tion since 2004. Our analysis assessed the survival of
GISTs by three time periods: 1) 1998–2001, before the
approval imatinib to treat GISTs; 2) 2002–2004, after the
approval of imatinib to treat GISTs and before the cover-
age of imatinib by the National Health Insurance of
Taiwan; and 3) 2005–2008, after the coverage of imatinib
by the National Health Insurance of Taiwan.
Methods
Data sources
The GIST cases diagnosed from January 1, 1998 to
December 31, 2008 were identified from the TCR estab-
lished in 1979 to track the cancer incidence and mortal-
ity in Taiwan [13]. Hospitals with more than 50 beds in
Taiwan are mandated to report confirmed cases of ma-
lignancy to the TCR, which captures 97% of the cancer
cases in Taiwan [13]. The quality of a cancer registry is
measured by the percentage of death certificate only
cases (DCO%) and the percentage of morphologically
verified cases (MV%), with a DCO% of 0 and a MV% of
100 representing a perfect data quality [14]. The quality
of the TCR is comparable to the other well-established
cancer registries in the world [15,16] with a DCO% of
1.2% and a MV% of 89% [13].
Study population
Before 2002, the diagnosis of GISTs by CD117 or c-KIT
staining was unavailable; therefore, for cases diagnosed
from January 1, 1998 to December 31, 2001, the morph-
ology (M) codes of the International Classification of
Disease for Oncology, Field Trial Edition (ICD-O-FT)
were used to identify GIST cases with the algorithm estab-
lished by Tran et al. [17], which included stromal sarcoma
(8930), leiomyosarcoma (8890), epithelioid leiomyosar-
coma (8891), cellular leiomyosarcoma (8892), bizarre
leiomyosarcoma (8893), myxoid leiomyosarcoma (8896),
smooth muscle cell tumor (8897), sarcoma not other-
wise specified (8800), spindle cell sarcoma (8801), giant
cell sarcoma (8802), small cell sarcoma (8803), epithelioid
sarcoma (8804), mesenchymoma (8990), fibrosarcoma
(8810), fibromyxosarcoma (8811), ganglioneuroma (9490),
ganglioneuromatosis (9491), neurobalstoma (9500), neu-
roepithelioma (9503), ganglioglioma (9505), neurofibroma(9504), schwannoma (9650), paragangmaluganglioma
(8680), glomus tumor (8711), angiosarcoma (9120),
and hemangiopericytoma (9150). The origin of tumors
was limited to the following primary sites: esophagus,
stomach, small intestine, colon and rectum. In addition,
only those with confirmed malignant behavior by histo-
logical criteria (ICD-O-FT fifth digit of /3) were included.
GISTs diagnosed after January 1, 2002 were identified by
the International classification of Diseases for Oncology,
Third Edition (ICD-O-3) with the M code for gastrointes-
tinal stromal sarcoma (8936). Only cases with confirmed
malignant neoplasm (ICD-O-3 fifth digit of /3) were
included.
Statistical analysis
The crude annual incidence was calculated by dividing the
number of annual incident GIST cases by the annual
population reported by the Directorate-General of Budget,
Accounting, and Statistics of Taiwan (http://www.dgbas.
gov.tw). The crude incidence rates were calculated for all
GISTs combined, by sex, and by primary sites. All inci-
dence rates (per 100,000) were age-adjusted to the 2000
U.S. standard population to generate the age-standardized
incidence rates. The observed overall survival (OS) rates
were calculated for all patients and by sex, primary sites,
and diagnostic periods. Patients were followed from the
date of diagnosis to death recorded in the national death
database or to the end of follow-up on December 31,
2010. Cox proportional hazards models were performed
to generate hazard ratios (HRs) and 95% confidence inter-
vals (CIs) for the risk of mortality associated with tumor
site, sex, age, and the year of diagnosis. Stage at diagnosis
(localized or metastatic), tumor size, and mitotic index
were excluded from the analysis because of incomplete or
lack of information. This study was approved by the Insti-
tutional Review Board of the National Health Research
Institutes.
Results
Characteristics of GIST patients
During 1998–2008, 2,986 newly diagnosed GIST cases
were recorded by the TCR. The age of GIST patients
ranged from 18 to 96 years old. The median age was
around 62–64 years old and almost 75% of cases were
diagnosed at ≧50 years of age (Table 1). For both sexes,
the most common primary sites of GISTs were stomach
(47-59%), followed by small intestine (31-38%), and
colon/rectum (6-9%).
A higher percentage of GIST originated from the small
intestine was observed among those aged <50 years, and
this percentage decreased with increasing age (from
43.8% among those younger than 50 years to 28.7% for
those aged 70 years or older in 1998–2001; from 42.1%
among those younger than 50 years to 31.4% for those





















<50 100 (26.6%) 78 (28.0%) 115 (24.8%) 86 (22.5%) 159 (19.9%) 129 (18.9%)
50 to <60 70 (18.6%) 50 (17.9%) 89 (19.2%) 91 (23.8%) 191 (23.9%) 162 (23.7%)
60 to <70 108 (27.1%) 74 (26.5%) 116 (25%) 96 (25.1%) 200 (25.0%) 184 (26.9%)
70 to <80 78 (20.7%) 68 (24.4%) 118 (25.4%) 86 (22.5%) 182 (22.7%) 157 (23.0%)
>80 26 (6.9%) 9 (3.2%) 26 (5.6%) 23 (6.0%) 69 (8.6%) 52 (7.6%)
Median (min/max) 62 (26/87) 62 (23/88) 63 (19/89) 62 (18/91) 64 (19/96) 64 (22/94)
Location
Stomach 199 (52.9%) 164 (58.8%) 217 (46.8%) 196 (51.3%) 395 (49.3%) 375 (54.8%)
Small intestine 143 (38.0%) 94 (33.7%) 177 (38.2%) 125 (32.7%) 289 (36.1%) 213 (31.1%)
Colon/rectum 30 (8.0%) 20 (7.2%) 39 (8.4%) 34 (8.9%) 45 (5.6%) 43 (6.3%)
Esophagus/othersa 4 (1.1%) 1 (0.4%) 31 (6.7%) 27 (7.1%) 72 (9.0%) 53 (7.8%)
aOthers: retroperitoneum and unspecific sites.
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the percentage of GIST originated from the stomach in-
creased with age (from 48.3% among those younger than
50 years to 63.0% for those aged 70 years or older in 1998–
2001; from 42.9% among those younger than 50 years to
54.3% for those aged 70 years or older in 2002–2008). No
significant trend was observed for the percentages of GISTs
in colon/rectum or esophagus/others by increasing age.
Incidence rates of GIST
The age-standardized annual incidence rate increased
from 1.13/100,000 in 1998, to 1.25/100,000 in 2002, and
to 1.97/100,000 in 2008 (Table 3 and Figure 1A). DuringTable 2 Distribution of gastrointestinal stromal tumors






50 to < 60
N = 120




Stomach 86 (48.3%) 68 (56.7%) 95 (54.0%) 114 (63.0%)
Small intestine 78 (43.8%) 41 (43.8%) 66 (37.5%) 52 (28.7%)
Colon/rectum 12 (6.7%) 11 (9.2%) 15 (8.5%) 12 (6.6%)




50 to < 60
N = 533




Stomach 210 (42.9%) 266 (45.0%) 320 (53.7%) 387 (54.3%)
Small intestine 206 (42.1%) 182 (34.2%) 192 (32.2%) 224 (31.4%)
Colon/rectum 36 (7.4%) 45 (8.4%) 40 (6.7%) 40 (5.6%)
Esophagus/othersa 37 (7.6%) 40 (7.5%) 44 (7.4%) 62 (8.7%)
aOthers: retroperitoneum and unspecific sites.2002–2008, men consistently had a slightly higher inci-
dence rate of GIST than women (male to female ratio
ranged from 1.02 to 1.26). The incidence rate increased
gradually during 1998–2008, but more prominently after
2002. There was a rise in the incidence of GIST located
in stomach, small intestine, and esophagus/others(retro-
peritoneum and unspecified sites), whereas the incidence
of GIST in colon/rectum remained relatively stable
(Table 3 and Figure 1B).
Survival of GIST patients
Overall, the 1-yr observed OS rate was 88% and the 5-yr
observed OS rate was 66.5% (Table 4). There was a signifi-
cant sex difference in survival (p < .0001) (Table 4). For
men, the 1- and 5-yr observed OS rates were 86% and
60.3%, respectively. For women, the 1- and 5-yr observed
OS rates were 90.6% and 74.2%, respectively. Patients with
GISTs from colon/rectum had the best prognosis with a
5-yr observed OS rate of 72.4%, followed by stomach
(69.4%), and small intestine (65.1%) (Table 4). Women had
a better prognosis than men for all sites. Among men, the
5-yr observed OS rate was 66.6%, 62.1% and 60.7% for
GIST in colon/rectum, stomach, and small intestine, re-
spectively. For women, the 5-yr observed OS rate was
78.7%, 77.5% and 71.3% for GIST in colon/rectum, stom-
ach, and small intestine, respectively. The 5-yr observed
OS rate for all patients improved from 58.9% during
1998–2001 to 67.0% during 2002–2004 and to 70.2% dur-
ing 2005–2008 (Table 4 and Figure 2).
Age, sex, primary site, and the year of diagnosis inde-
pendently predicted the mortality of GIST (Table 5). Pa-
tients older than 50 years had a 1.4 to 5.7 fold increase
in the risk of death compared to those younger than
Table 3 Age-standardized incidence (per 100,000) of gastrointestinal stromal tumors, Taiwan, 1998-2008a
Year Total Gender Primary sites
Male Female Stomach Small intestine Colon/rectum Esophagus/othersb
1998 1.13 1.03 1.24 0.53 0.31 0.11 0.01
1999 1.20 1.17 1.22 0.56 0.37 0.08 0.01
2000 1.14 1.06 1.22 0.53 0.32 0.07 0.02
2001 1.05 1.04 1.07 0.52 0.30 0.04 0.00
2002 1.25 1.26 1.23 0.66 0.40 0.11 0.09
2003 1.55 1.72 1.39 0.74 0.57 0.13 0.11
2004 1.59 1.79 1.38 0.79 0.58 0.11 0.10
2005 1.64 1.81 1.46 0.9 0.52 0.10 0.12
2006 1.70 1.77 1.63 0.88 0.57 0.12 0.12
2007 1.75 1.91 1.59 0.91 0.60 0.09 0.15
2008 1.97 2.20 1.75 1.00 0.65 0.12 0.20
aAge-standardized to the 2000 US standard population.
bOthers: retroperitoneum and unspecific sites.
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(HR = 0.68, 95% CI: 0.60-0.77, P < 0.0001). GISTs arising
from the stomach had better prognosis than those from
the small intestine regardless of the time periods, but
this difference became non-statistically significant duringFigure 1 The incidence rate of gastrointestinal stromal tumors,
Taiwan, 1998–2008: A) Overall and by sex; B) By primary sites.2005–2008 (P = 0.12, Additional file 1: Table S1, S2, and
S3). Compared with those diagnosed in 2005–2008, pa-
tients diagnosed in 1998–2001 (HR = 1.67, 95% CI: 1.42-
1.97) and 2002–2004 (HR = 1.25, 95% CI: 1.08-1.46) had
a significantly higher risk of mortality (Table 5).
Discussion
Results of this first Asian nation-wide cancer registry-
based study of GISTs showed that the annual incidence of
GISTs in Taiwan ranged from 1 to 2 cases per 100,000. In
a hospital-based retrospective cohort study, Tzen et al. es-
timated that the incidence of GIST in Taiwan during
1998–2004 was 1.37 cases per 100,000, which was similar
to our result [18]. In a hospital-based retrospective cohort
study, the annual incidence of GISTs in Hong Kong was
estimated to be 1.68-1.96 per 100,000 [4]. In a study based
on pathology reports from 38 hospitals, Cho et al. re-
ported that the incidence of GISTs in Korea was approxi-
mately 1.6-2.2 per 100,000 [19]. Studies from Europe and
North America reported a GIST incidence of 1.45 per
100,000 in Sweden [20], 0.65-0.90 per 100,000 in Spain
[21], 0.6-1.9 per 100,000 in Norway [22], 0.66 in Italy [23],
0.85-1.00 per 100,000 in France [24], 0.9 per 100,000 in
Canada [25], 1.32 per 100,000 in United Kingdom [26],
and 0.7 per 100,000 in USA [17]. Given the different study
time periods and the lack of confirmation by KIT immu-
nohistochemical staining in some studies, it is difficult to
compare the incidence rates of GISTs across different
countries; however, the published literature to date
showed that the incidence rates of GISTs in different
countries appeared to fall in a similar range.
Our analysis indicated that the incidence of GISTs in
Taiwan increased during 1998–2008, with a more prom-
inent rise since 2002 (Table 3 and Figure 1A). The pos-
sible reasons for the observed rise in the incidence of




1-year survival 5-year survival
Overall Male Female P valuea Overall Male Female P valuea
All sites 88.0% 86.0% 90.6% <.0001 66.5% 60.3% 74.2% <.0001
Stomach 90.1% 87.7% 92.8% <.0001 69.4% 62.1% 77.5% <.0001
Small intestine 88.1% 86.5% 90.3% 0.0009 65.1% 60.7% 71.3% 0.0008
Colon/rectum 87.7% 89.5% 85.6% 0.1666 72.4% 66.6% 78.7% 0.0732
Esophagus/othersb 71.3% 66.4% 77.8% 0.1321 43.4% 36.8% 51.9% 0.0897
1998-2001
All sites 81.8% 78.5% 86.4% <.0001 58.9% 52.7% 67.4% <.0001
Stomach 85.1% 80.4% 90.9% 0.0010 61.4% 53.3% 71.3% 0.0006
Small intestine 77.6% 75.5% 80.9% 0.0336 55.3% 52.5% 59.6% 0.0368
Colon/rectum 80% 80% 80% 0.1118 60% 50% 75% 0.0519
Esophagus/othersb 60% 75% – – 40% 50% – –
2002-2004
All sites 90.0% 87.5% 92.9% <.0001 67.0% 59.7% 76.0% <.0001
Stomach 91.0% 88.5% 93.9% <.0001 70.2% 61.3% 80.1% <.0001
Small intestine 90.4% 89.3% 92.0% 0.4008 64.9% 59.9% 72.0% 0.2272
Colon/rectum 94.5% 94.9% 94.1% 0.4290 80.8% 74.4% 88.2% 0.3414
Esophagus/othersb 74.1% 61.3% 88.9% 0.0947 37.9% 29.0% 48.2% 0.1277
2005-2008
All sites 89.7% 88.6% 90.9% <.0001 70.2% 65.5% 75.8% <.0001
Stomach 92.0% 90.9% 93.1% 0.0006 73.2% 68.9% 77.8% 0.0004
Small intestine 91.6% 90.3% 93.4% 0.0081 70.5% 65.9% 76.9% 0.0103
Colon/rectum 86.4% 91.1% 81.4% 0.8154 74.1% 75.3% 73.0% 0.9534
Esophagus/othersb 70.4% 68.1% 73.6% 0.1976 46.9% 37.7% 58.7% 0.1796
aThe P-value for gender difference was calculated by the Kaplan-Meier method.
bOthers: retroperitoneum and unspecific sites.
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tion, the advancement of diagnostic technology/method,
and the increased awareness of GISTs by physicians
which could be partly attributed to the emergence of ef-
fective targeted therapeutic agent, imatinib. Previously,Figure 2 The 5-yr observed overall survival rate of gastrointestinal
stromal tumors by primary sites and diagnostic periods
(1998–2001, 2002–2004, and 2005–2008), Taiwan, 1998–2008
(*Others: retroperitoneum and unspecific sites).GISTs might have been misclassified as leiomyosarcoma,
leiomyoma or unspecified sarcoma. The exact diagnosis
and tumor origin of GISTs were difficult to determine
until the discovery of the gain-of-function mutation in
the KIT oncogene. In Taiwan, the routine use of CD117
or KIT immunohistochemical staining to diagnose GIST
began in 2002. Before 2002, the diagnosis of GIST was
based on histology with variable use of staining markers.
In addition, no unique code indicating “gastrointestinal
stromal sarcoma” was available in the ICD-O-FT, which
was used by the TCR before 2002. The rising incidence
of GISTs in Taiwan might be attributed to the increased
utilization of CD117 staining and the increased aware-
ness of GIST by the physicians. Nevertheless, there was
still a rising trend of GIST incidence from 2005 to 2008,
during which the use of CD117 or KIT immunohisto-
chemical staining had already been widely adopted for
the diagnosis of GISTs. Further follow-up is necessary to
clarify whether the incidence of GISTs is truly on the
Table 5 Survival analysis of patients with gastrointestinal stromal tumors, Taiwan, 1998-2008
Univariable Multivariable
Sex HRa 95% CIa P HRa 95% CIa P
Male Referent Referent
Female 0.61 0.54–0.69 <.0001 0.68 0.60–0.77 <.0001
Age, years
< 50 Referent Referent
50 to <60 1.23 1.00–1.52 0.053 1.40 1.14–1.73 <.0001
60 to < 70 1.51 1.24–1.83 <.0001 1.74 1.44–2.12 <.0001
70 to < 80 2.73 2.27–3.27 <.0001 3.08 2.56–3.71 <.0001
> 80 4.58 3.64–5.75 <.0001 5.69 4.51–7.17 <.0001
Primary site
Stomach Referent Referent
Small intestine 1.27 1.11–1.44 0.0003 1.35 1.18–1.54 <.0001
Colon/rectum 1.05 0.82–1.34 0.6954 1.08 0.85–1.38 0.5164
Esophagus/othersb 2.65 2.14–3.27 <.0001 2.51 2.01–3.12 <.0001
Year of diagnosis
2005–2008 Referent Referent
1998–2001 1.42 1.21–1.65 <.0001 1.67 1.42–1.97 <.0001
2002–2004 1.23 1.06–1.43 0.0056 1.25 1.08–1.46 0.0035
aHazard ratio (HR) and 95% confidence interval (CI) were calculated based on Cox proportional hazards model.
bOthers: retroperitoneum and unspecific sites.
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incidence of GIST arising from esophagus/others com-
pared to those from colon/rectum, especially during the
2002–2008 period. (Table 3 and Figure 1B). The increase
in the incidence of GIST from esophagus/others resulted
mostly from the elevated incidence of GIST located in
retroperitoneum and unspecific sites (separate data not
shown). The increased awareness of physicians with a more
active approach to tumors arising from non-gastrointestinal
sites due to the progress in the diagnostic tools and the
availability of targeted therapy may partially account for this
finding.
In our study, there was a slight male predominance
(M/F ratio = 1.0 ~ 1.3) in the incidence of GISTs, which
was also observed by studies from Korea (M/F ratio = 1.1)
[19], Norway (M/F ratio = 1.6) [22], and the United States
(M/F ratio = 1.46) [17]. However, other studies reported a
female excess in the number of GISTs [23-26], while one
study reported no difference by sex [20]. Taken together, it
is not clear whether there is a sex difference in the inci-
dence of GIST, and if existed, may be insignificant. The
age distribution of GIST patients in our study is consistent
with those reported in the literature, with the majority of
GIST patients being diagnosed during the fifth to the
seventh decade of life. GISTs are occasionally found in
young adults, but rarely among those younger than
18 years of age. In our series, stomach was the most fre-
quent site of involvement (47-59%) followed by smallintestine (31-38%) and colon/rectum (6-9%). The site dis-
tribution of GISTs in our study is consistent with those
published in the previous literature (stomach: 50-64%, small
intestine: 17-44%, and colon/rectum: 2-19%) [17,19-26]. In
our study, the percentage of GISTs originated from stom-
ach increased with age, while the percentage of GISTs origi-
nated in the small intestine decreased with age. To our
knowledge, our study is the first to report this interesting
finding, which could partially be explained by the more ag-
gressive clinical behavior of small intestine GIST [27]. The
more aggressive clinical course and thus the earlier signs
and symptoms of GIST from the small intestine as opposed
to the more indolent behavior of GIST from other sites
may lead to the diagnosis of small intestine GIST at a youn-
ger age. However, more investigations are needed to deter-
mine the causes for the differences in the percentages of
GIST location with increasing age.
Surgery remains the optimal therapy for the curative
treatment of GISTs, but unfortunately, more than 50% of
patients will develop recurrence or metastasis. Single or
combined cytotoxic chemotherapy have failed to yield a
satisfactory response. Prior to the introduction of tyrosine
kinase inhibitors, the outcome for patients with me-
tastatic disease was poor with a median survival of < 2 years
[28]. The prognosis of GIST improved dramatically after
the introduction of imatinib, a tyrosine kinase inhibitor ap-
proved by the FDA in 2002 for treating KIT-positive GIST
[29]. In Taiwan, imatinib became widely prescribed for
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by the National Health Insurance Administration in 2004.
In our analysis by the three time periods, the 5-yr observed
OS rate of GISTs improved with the introduction of ima-
tinib as a GIST treatment (1998–2001: 59% vs. 2002–2004:
67%), and further improved with the approved coverage of
imatinib by the National Health Insurance Administration
(as a proxy for a wider usage) (2005–2008: 70%). This is
consistent with previous literature, with GISTs diag-
nosed in the pre-imatinib era having a 5-year survival
ranging from 45% to 63% [4,17,21,22] and GISTs occur-
ring in the imatinib era having a better 5-year survival
(79%) [30].
In our analysis, besides the year of diagnosis, female sex,
younger age, and stomach location were independent fa-
vorable prognostic factors of survival. The impact of the
anatomic sites of GIST on survival is equivocal in the lit-
erature. In some studies, GIST arising from the stomach
was less aggressive than those from other sites while other
studies showed no difference [10,31,32]. Our study
showed that GIST arising from the stomach had a better
survival rate than those affecting the small intestine. Not-
ably, GIST from the colon/rectum exhibited the best 5-yr
observed OS of 72.4%, although this survival advantage
over GIST in the small intestine disappeared in the multi-
variable analysis, after adjusting for sex, age, and the year
of diagnosis. The difference in survival between GISTs in
the stomach and GISTs in the small intestine decreased
with time (6.1% in 1998–2001; 5.2% in 2002–2004; 2.7% in
2005–2008), which could be attributed to the advance-
ment in treatment, such as the use of imatinib. In our
multivariable analysis, female sex was an independent fa-
vorable prognostic factor for survival (Table 5). The mag-
nitude of survival advantage of women over men persisted
(Additional file 1: Table S1, S2, S3) even during the era of
imatinib treatment. Using SEER data, Tran et al. observed
a survival advantage of women over men (women vs. men:
5-yr mortality risk HR = 0.83, 95% CI: 0.71-0.97) [17]. Simi-
larly, in another cancer registry-based study of 46 c-KIT
confirmed cases diagnosed in 1994–2001, women had a
better 5-year survival than men (75% vs. 52%) [21]. In a co-
hort of 1,215 GISTs patients diagnosed between May, 2000
and October 2010, Call et al. also reported a better GIST
survival in women compared to men (men vs. women:
HR = 1.5, 95% CI: 1.2-1.8) [30]. It is unclear what contrib-
utes to the better survival of GISTs among women com-
pared to men and further investigations are warranted.
This study has several strengths. This is the first
nation-wide cancer registry-based study of GIST and
one of the largest GIST studies from Asia. Because the
GIST cases were identified from a nation-wide cancer
registry, our results are population-based with a reduced
probability of selection bias associated with identifying
GISTs from a single or a few medical institutions. The othermajor strength is the long study period from 1998–2008,
which spanned across the eras of pre-imatinib, transition,
and imatinib, and allowed us to demonstrate the influence
of change in treatment practice on the survival of GIST
patients.
This study has several limitations. The TCR does not
have complete information on the tumor size of GISTs
and lacks data on mitotic index; therefore, risk stratifi-
cation according to the Armed Forces Institute of Path-
ology (AFIP) criteria (also known as Miettinen’s criteria)
to predict the prognosis of GISTs was not possible [33].
We used multiple ICD-O codes to represent GIST diag-
nosed in 1998–2001 due to the lack of an ICD-O code
specific for GIST and the absence of confirmation by
c-KIT staining. As a result, the incidence rates for
1998–2001 might have been overestimated due to the
potential inclusion of other non-GIST mesenchymal
tumors. However, studies suggested that that the ma-
jority of gastrointestinal tumors previously classified as
tumors of smooth muscle, including leiomyosarcoma
or nerve sheath tumors were GISTs [2,34], which is con-
sistent with our GISTs cases identified for the 1998–
2001 period (83.5% was leiomyosarcoma, followed by
8.85% of sarcoma, not otherwise specified, and 3.36% of
epithelioid leiomyosarcoma). In addition, compared to
GISTs diagnosed during 2002–2008 after the establish-
ment of c-KIT staining as part of the diagnostic protocol
and identified by a single ICD-O-3 code (8936: gast-
rointestinal stromal sarcoma), GISTs from 1998–2001
showed similar distributions of sex, age, and primary sites
(Table 1), supporting that the majority of our cases from
1998–2001 were likely GIST. Finally, although our analysis
suggested that the introduction and the wider use of ima-
tinib could contribute to the improved survival of GIST
patients, it is possible that other factors may have en-
hanced the survival of GIST patients, including increased
awareness of the disease, earlier diagnosis, improved treat-
ment, and better overall population health.
Conclusions
The incidence of GISTs in Taiwan is comparable to
those reported by the US and European studies. GIST is a
rare cancer in Taiwan and its incidence has been increas-
ing gradually, partially due to the advancement of diagnos-
tic technology/method and the increased awareness of
GISTs by physicians. The occurrence of GISTs is more
common in men and the older population. The stomach is
the most common primary site followed by the small in-
testine. Prognostic factors for a better survival of GIST in-
clude female sex, younger age, stomach location, and
diagnostic years (likely as a proxy for change in treatment
practice). Finally, our results suggest that the survival of
patients with GIST has improved significantly by targeted
therapy.
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